One Extension Entomologist\u27s Perspective on BT Transgenic Corn

The title is very important it is my opinion based on what I now know about Bt corn. I say NOW because this technology is on a very fast track and new information is added almost daily. From a gene deployment and resistance management point of view of Bt corn, there are many, many unknowns. All of us are learning on the go

Population Suppression of Western Corn Rootworm by Adult Control with ULV Malathion

ULV malathion (9.7 oz AI/acre) was applied by air to a 16 square-mile area during August of 1968, 1969, and 1970. Adult Diabrotica virgifera LeConte populations were reduced the following season by 39, 54, and 72%. No economic infestations occurred in the treated area the year following any application. Postspray migration of beetles was very limited, but adult migration during the peak emergence period the following season contributed to repopulation of the treated area. Migration and fecundity appear to be density-dependent factors which favor increases under low populations. Area suppression does not appear economically feasible, but adult control in individual fields may be an acceptable alternative to soil insecticides applied for larval control. A model was developed for timing treatments against adults; treatments between Aug. 1–15 should result in adequate population suppression to prevent damage the following season. Mid-August population levels of 1.0 beetle/ plant were an acceptable economic threshold for determining the need for control measures

Field Worker Exposure to Selected Insecticides Applied to Com Via Center-Pivot Irrigation

Field workerswere monitored for dermal and respiratory exposure to chlorpyrifos (with and without crop oil), carbaryl, and permethrin at reentry intervals of 2, 4, 8, 24, and 48 h after application. Insecticides were applied to R3 stage corn through an overhead center-pivot irrigation system. Dermal exposure was measured by analyzing 18 gauze pads attached to the clothing of workers to represent human body regions. Hand exposure was determined using cotton gloves. Respiratory exposure was determined using portable air samplers equipped with polyurethane foam plugs to trap ambient insecticide residues. Gas liquid chromatography was used to quantify residues of chlorpyrifos and permethrin in gauze pads, gloves, and foam plugs. Carbaryl residues in pads, gloves, and foam plugs were analyzed using high-performance liquid chromatography. Highest dermal and respiratory exposures were found at the 2-h reentry interval. Exposures decreased as reentry interval increased. Dermal exposure was primarily confined to the hands. Residues detected by air samplers ranged from 0 to 0.03 μg/liter. Based on the estimated percentages of acute toxic dose (all \u3c0.00038%), the risk of acute toxicity to workers at the intervals studied was low

NF97-343 Returning CRP Land to Crops: Warm-Season Grass Management/Cropping Suggestions

This NebFact has information on returning CRP land to crop production including tillage and no-till recommendations

NF97-343 Returning CRP Land to Crops: Warm-Season Grass Management/Cropping Suggestions

This NebFact has information on returning CRP land to crop production including tillage and no-till recommendations

Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial

IMPORTANCE: Secretory phospholipase A2(sPLA2) generates bioactive phospholipid products implicated in atherosclerosis. The sPLA2inhibitor varespladib has favorable effects on lipid and inflammatory markers; however, its effect on cardiovascular outcomes is unknown. OBJECTIVE: To determine the effects of sPLA2inhibition with varespladib on cardiovascular outcomes. DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, multicenter trial at 362 academic and community hospitals in Europe, Australia, New Zealand, India, and North America of 5145 patients randomized within 96 hours of presentation of an acute coronary syndrome (ACS) to either varespladib (n = 2572) or placebo (n = 2573) with enrollment between June 1, 2010, and March 7, 2012 (study termination on March 9, 2012). INTERVENTIONS: Participants were randomized to receive varespladib (500 mg) or placebo daily for 16 weeks, in addition to atorvastatin and other established therapies. MAIN OUTCOMES AND MEASURES: The primary efficacy measurewas a composite of cardiovascular mortality, nonfatal myocardial infarction (MI), nonfatal stroke, or unstable angina with evidence of ischemia requiring hospitalization at 16 weeks. Six-month survival status was also evaluated. RESULTS: At a prespecified interim analysis, including 212 primary end point events, the independent data and safety monitoring board recommended termination of the trial for futility and possible harm. The primary end point occurred in 136 patients (6.1%) treated with varespladib compared with 109 patients (5.1%) treated with placebo (hazard ratio [HR], 1.25; 95%CI, 0.97-1.61; log-rank P = .08). Varespladib was associated with a greater risk of MI (78 [3.4%] vs 47 [2.2%]; HR, 1.66; 95%CI, 1.16-2.39; log-rank P = .005). The composite secondary end point of cardiovascular mortality, MI, and stroke was observed in 107 patients (4.6%) in the varespladib group and 79 patients (3.8%) in the placebo group (HR, 1.36; 95% CI, 1.02-1.82; P = .04). CONCLUSIONS AND RELEVANCE: In patients with recent ACS, varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of MI. The sPLA2inhibition with varespladib may be harmful and is not a useful strategy to reduce adverse cardiovascular outcomes after ACS. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130246. Copyright 2014 American Medical Association. All rights reserved

The Demise of Islet Allotransplantation in the US: A Call for an Urgent Regulatory Update The ISLETS FOR US Collaborative

Islet allotransplantation in the United States (US) is facing an imminent demise. Despite nearly three decades of progress in the field, an archaic regulatory framework has stymied US clinical practice. Current regulations do not reflect the state-of-the-art in clinical or technical practices. In the US, islets are considered biologic drugs and more than minimally manipulated human cell and tissue products (HCT/Ps). Across the world, human islets are appropriately defined as minimally manipulated tissue which has led to islet transplantation becoming a standard-of-care procedure for patients with type 1 diabetes mellitus and problematic hypoglycemia. As a result of the outdated US regulations, only eleven patients underwent allo-ITx in the US between 2011-2016 and all in the setting of a clinical trial. Herein, we describe the current regulations pertaining to islet transplantation in the United States. We explore the progress which has been made in the field and demonstrate why the regulatory framework must be updated to both, better reflect our current clinical practice and to deal with upcoming challenges. We propose specific updates to current regulations which are required for the renaissance of ethical, safe, effective, and affordable allo-ITx in the United States

Globetrotting strangles: the unbridled national and international transmission of Streptococcus equi between horses.

The equine disease strangles, which is characterized by the formation of abscesses in the lymph nodes of the head and neck, is one of the most frequently diagnosed infectious diseases of horses around the world. The causal agent, Streptococcus equi subspecies equi, establishes a persistent infection in approximately 10 % of animals that recover from the acute disease. Such 'carrier' animals appear healthy and are rarely identified during routine veterinary examinations pre-purchase or transit, but can transmit S. equi to naïve animals initiating new episodes of disease. Here, we report the analysis and visualization of phylogenomic and epidemiological data for 670 isolates of S. equi recovered from 19 different countries using a new core-genome multilocus sequence typing (cgMLST) web bioresource. Genetic relationships among all 670 S. equi isolates were determined at high resolution, revealing national and international transmission events that drive this endemic disease in horse populations throughout the world. Our data argue for the recognition of the international importance of strangles by the Office International des Épizooties to highlight the health, welfare and economic cost of this disease. The Pathogenwatch cgMLST web bioresource described herein is available for tailored genomic analysis of populations of S. equi and its close relative S. equi subspecies zooepidemicus that are recovered from horses and other animals, including humans, throughout the world. This article contains data hosted by Microreact

Personality traits, consumer animosity, and foreign product avoidance: The moderating role of individual cultural characteristics

Although personality and cultural traits were found to be important predictors or moderators of consumer attitudes and behavior, their relationship to consumer animosity has not yet been studied. This article reports the findings of a study conducted among 606 Ukrainian consumers, aiming to identify personality drivers and behavioral outcomes of consumer animosity, as well as the moderating role of cultural characteristics. Structural equation modeling revealed that extraversion and conscientiousness have a negative effect on consumer animosity, while neuroticism and openness are positively associated with this feeling. However, no significant relationship was observed between animosity and agreeableness. In turn, consumer animosity was found to influence product avoidance, with this association becoming stronger in the case of consumers with higher levels of power distance, uncertainty avoidance, collectivism, and masculinity. The study also showed that male and educated consumers are more likely to harbor animosity toward a hostility-evoking country, while age and income had no control effect on animosity. Several implications for theory and practice are derived from the study findings, and directions for future research are provided

Lysyl-tRNA synthetase as a drug target in malaria and cryptosporidiosis

Malaria and cryptosporidiosis, caused by apicomplexan parasites, remain major drivers of global child mortality. New drugs for the treatment of malaria and cryptosporidiosis, in particular, are of high priority; however, there are few chemically validated targets. The natural product cladosporin is active against blood- and liver-stage; Plasmodium falciparum; and; Cryptosporidium parvum; in cell-culture studies. Target deconvolution in; P. falciparum; has shown that cladosporin inhibits lysyl-tRNA synthetase (; Pf; KRS1). Here, we report the identification of a series of selective inhibitors of apicomplexan KRSs. Following a biochemical screen, a small-molecule hit was identified and then optimized by using a structure-based approach, supported by structures of both; Pf; KRS1 and; C. parvum; KRS (; Cp; KRS). In vivo proof of concept was established in an SCID mouse model of malaria, after oral administration (ED; 90; = 1.5 mg/kg, once a day for 4 d). Furthermore, we successfully identified an opportunity for pathogen hopping based on the structural homology between; Pf; KRS1 and; Cp; KRS. This series of compounds inhibit; Cp; KRS and; C. parvum; and; Cryptosporidium hominis; in culture, and our lead compound shows oral efficacy in two cryptosporidiosis mouse models. X-ray crystallography and molecular dynamics simulations have provided a model to rationalize the selectivity of our compounds for; Pf; KRS1 and; Cp; KRS vs. (human); Hs; KRS. Our work validates apicomplexan KRSs as promising targets for the development of drugs for malaria and cryptosporidiosis